Literature DB >> 6587901

Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.

J S Lilleyman, L Lennard, C A Rees, G Morgan, J L Maddocks.   

Abstract

Twelve boys and 10 girls on similar long term remission maintenance treatment for lymphoblastic leukaemia had 79 random assays of their red cell 6 thioguanine nucleotide ( 6TGN ) concentrations performed as an index of cytotoxic activity generated by oral 6-mercaptopurine ( 6MP ). Correlation between the dose of 6MP and 6TGN was statistically significant in the girls (r = 0.58, P less than 0.001) but not in the boys (r = 0.15). Additionally, as a group the boys tolerated more 6MP (P less than 0.05), despite similar prescribing criteria, but this did not result in a higher mean 6TGN concentration or increased myelotoxicity. It appears that girls develop 6MP cytotoxicity at lower doses and more predictably than boys. If so, this may be relevant to the as yet unexplained but marked sex difference in prognosis apparent in some studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587901      PMCID: PMC1976838          DOI: 10.1038/bjc.1984.111

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

Review 1.  The ninth annual David Karnofsky Lecture. Treatment of acute lymphocytic leukemia.

Authors:  D Pinkel
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

2.  A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine.

Authors:  D M Tidd; A R Paterson
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

3.  A reappraisal of the results of stopping therapy in childhood leukemia.

Authors:  S L George; R J Aur; A M Mauer; J V Simone
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

4.  Assay of thioinosinic acid, an active metabolite of azathioprine, in human lymphocytes.

Authors:  L Fletcher; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

5.  Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia.

Authors:  C A Rees; L Lennard; J S Lilleyman; J L Maddocks
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.

Authors:  L Lennard; J L Maddocks
Journal:  J Pharm Pharmacol       Date:  1983-01       Impact factor: 3.765

7.  Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis.

Authors:  M F Greaves; G Janossy; J Peto; H Kay
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

8.  6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia.

Authors:  S Herber; L Lennard; J S Lilleyman; J Maddocks
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

  8 in total
  8 in total

1.  Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.

Authors:  J P Hale; J S Lilleyman
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

2.  DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.

Authors:  Hee Young Ju; Ji Won Lee; Hee Won Cho; Ju Kyung Hyun; Youngeun Ma; Eun Sang Yi; Keon Hee Yoo; Ki Woong Sung; Rihwa Choi; Hong Hoe Koo; Soo-Youn Lee
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

3.  6-Thioguanine: high-dose 2-H infusions in goats.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; M B van Leeuwen; J M van Baal; G A de Vaan
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

4.  Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population.

Authors:  B Klemetsdal; B Straume; E Wist; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Authors:  E Jacqz-Aigrain; E Bessa; Y Medard; Y Mircheva; E Vilmer
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

6.  Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia.

Authors:  L Lennard; J P Hale; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

7.  Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.

Authors:  G Escherich; S Richards; L C Stork; A J Vora
Journal:  Leukemia       Date:  2011-03-04       Impact factor: 11.528

Review 8.  Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.

Authors:  Hong-Li Guo; Yue-Tao Zhao; Wei-Jun Wang; Na Dong; Ya-Hui Hu; Yuan-Yuan Zhang; Feng Chen; Li Zhou; Tao Li
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.